# Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

> **NCT00119249** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 74 (estimated)

## Conditions studied

- Stage III Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00119249
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119249, "Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00119249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*